ARS Pharmaceuticals Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of ARS Pharmaceuticals Inc Company

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc Info



Ticker SymbolSPRY

Company nameARS Pharmaceuticals Inc

IPO dateDec 04, 2020

CEOMr. Richard E. Lowenthal

Number of employees155

Security typeOrdinary Share

Fiscal year-endDec 04

Address11682 El Camino Real, Suite 120

CitySAN DIEGO

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code92130

Phone18587719307

Websitehttps://ars-pharma.com/

Ticker SymbolSPRY

IPO dateDec 04, 2020

CEOMr. Richard E. Lowenthal

Company Executives of ARS Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-14.34%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-10.85%

Mr. Justin Chakma

Chief Business Officer

136.38K

--

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-3.33%

Mr. Michael Kelly

Independent Director

83.22K

--

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

--

Dr. Laura K. Shawver, Ph.D.

Director

--

Dr. Rajeev Dadoo, Ph.D.

Independent Director

--

Ms. Kathleen D. (Kathy) Scott

Chief Financial Officer

--

Dr. Pratik Shah, Ph.D.

Chairman of the Board

--

Name

Name/Position

Position

Shareholding

Change

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-14.34%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-10.85%

Mr. Justin Chakma

Chief Business Officer

136.38K

--

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-3.33%

Mr. Michael Kelly

Independent Director

83.22K

--

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Wed, Sep 3

Shareholders

Shareholder Types

Shareholders

Proportion

RA Capital Management, LP

11.07%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.70%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

Other

61.05%

Shareholders

Proportion

RA Capital Management, LP

11.07%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.70%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

Other

61.05%

Shareholder Types

Shareholders

Proportion

Hedge Fund

21.29%

Investment Advisor

19.12%

Investment Advisor/Hedge Fund

18.57%

Venture Capital

15.15%

Individual Investor

12.08%

Private Equity

8.39%

Corporation

4.88%

Research Firm

2.70%

Sovereign Wealth Fund

0.44%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

372

85.58M

86.60%

-4.54M

2025Q2

367

96.00M

97.76%

-11.66M

2025Q1

380

100.63M

102.48%

-12.75M

2024Q4

345

96.62M

99.42%

-14.07M

2024Q3

320

88.19M

90.90%

-18.52M

2024Q2

291

87.17M

89.94%

-20.35M

2024Q1

289

89.45M

92.60%

-16.44M

2023Q4

280

92.18M

96.08%

-6.49M

2023Q3

283

95.82M

104.35%

+1.21M

2023Q2

278

88.26M

96.94%

-730.20K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

RA Capital Management, LP

10.94M

11.07%

+80.00K

+0.74%

Sep 29, 2025

OrbiMed Advisors, LLC

8.29M

8.39%

--

Jun 30, 2025

Deerfield Management Company, L.P.

7.61M

7.7%

-2.11M

-21.74%

Jul 30, 2025

Lowenthal (Richard E)

6.83M

6.91%

-1.14M

-14.34%

Mar 31, 2025

Pratik Shah Living Trust

4.82M

4.88%

--

Mar 31, 2025

Tanimoto (Sarina)

4.57M

4.63%

-556.66K

-10.85%

Mar 31, 2025

SR One Capital Management, LP

4.01M

4.06%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.93M

3.98%

+47.01K

+1.21%

Jun 30, 2025

AllianceBernstein L.P.

3.83M

3.87%

-97.01K

-2.47%

Jun 30, 2025

The Vanguard Group, Inc.

3.25M

3.29%

-228.66K

-6.57%

Jun 30, 2025

Related ETFs



Updated: Thu, Oct 2

Name

Proportion

Invesco Dorsey Wright Healthcare Momentum ETF

0.86%

ALPS Medical Breakthroughs ETF

0.67%

First Trust Small Cap Growth AlphaDEX Fund

0.39%

SPDR S&P Biotech ETF

0.23%

First Trust Small Cap Core Alphadex Fund

0.19%

Direxion Daily S&P Biotech Bull 3X Shares

0.14%

Invesco Nasdaq Biotechnology ETF

0.12%

ProShares Ultra Nasdaq Biotechnology

0.12%

Principal U.S. Small-Cap ETF

0.09%

First Trust Multicap Growth Alphadex Fund

0.08%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion0.86%

ALPS Medical Breakthroughs ETF

Proportion0.67%

First Trust Small Cap Growth AlphaDEX Fund

Proportion0.39%

SPDR S&P Biotech ETF

Proportion0.23%

First Trust Small Cap Core Alphadex Fund

Proportion0.19%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.14%

Invesco Nasdaq Biotechnology ETF

Proportion0.12%

ProShares Ultra Nasdaq Biotechnology

Proportion0.12%

Principal U.S. Small-Cap ETF

Proportion0.09%

First Trust Multicap Growth Alphadex Fund

Proportion0.08%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data